What will it take for cannabis and natural compounds to truly enter the mainstream—from toothpaste to energy drinks?

In Part 2 of Trevor and Kirk’s conversation with biotech financier and cannabis strategist David Traylor, they discuss how major corporations might explore integrating cannabinoids like CBN and CBD and other natural products into everyday consumer products.

David explains how his Skunk Works Nature AI advisory group connects global companies with world-class experts in pharmacology, biotechnology, and regulatory strategy to develop cannabinoid and other natural product based innovations. From potential sleep-supporting CBN toothpaste, to the role of pharmacogenomics and personalized medicine, this episode explores how science, investment, and product development intersect in the cannabis, psychedelic and natural product sectors.

Trevor and Kirk also unpack the broader forces shaping the cannabis industry—stigma, regulatory barriers, banking challenges, and the tension between single-molecule pharmaceutical approaches vs. whole-plant medicine. Could big brands like PepsiCo or Red Bull be the catalyst that finally normalizes cannabinoid ingredients in consumer products? And what role does fear, policy, and economics play in slowing cannabis acceptance?

Listen now to learn how cannabis science, biotech innovation, and big-industry investment could reshape the future of medicine, consumer products, and natural compounds.

David Traylor - LinkedIn

Skunk Works Nature AI - website

Transcripts, papers and so much more at: reefermed.ca